Clinical Trial

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Study acronym: PALAVY
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-04-07; most recent amendment 2026-04-06.
Status change: Not Yet Recruiting → Recruiting 2021-07-26
Trial Details
NCT Number NCT04841148
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Johns Hopkins University, Translational Breast Cancer Research Consortium, Pfizer, Breast Cancer Research Foundation
Conditions Breast Cancer
Enrollment 96 participants
Start Date 2021-06-01
Primary Completion 2027-07 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-09